Literature DB >> 25576148

Cost-of-illness studies for bipolar disorder: systematic review of international studies.

Huajie Jin1, Paul McCrone.   

Abstract

BACKGROUND AND OBJECTIVES: Bipolar disorder (BD) may result in a greater burden than all forms of cancer, Alzheimer's disease and epilepsy. Cost-of-illness (COI) studies provide useful information on the economic burden that BD imposes on a society. Furthermore, COI studies are pivotal sources of evidence used in economic evaluations. This study aims to give a general overview of COI studies for BD and to discuss methodological issues that might potentially influence results. This study also aims to provide recommendations to improve practice in this area, based on the review.
METHODS: A search was performed to identify COI studies of BD. The following electronic databases were searched: MEDLINE, EMBASE, PsycInfo, Cochrane Database of Systematic Reviews, HMIC and openSIGLE. The primary outcome of this review was the annual cost per BD patient. A narrative assessment of key methodological issues was also included. Based on these findings, recommendations for good practice were drafted.
RESULTS: Fifty-four studies were included in this review. Because of the widespread methodological heterogeneity among included studies, no attempt has been made to pool results of different studies. Potential areas for methodological improvement were identified. These were: description of the disease and population, the approach to deal with comorbidities, reporting the rationale and impact for choosing different cost perspectives, and ways in which uncertainty is addressed.
CONCLUSIONS: This review showed that numerous COI studies have been conducted for BD since 1995. However, these studies employed varying methods, which limit the comparability of findings. The recommendations provided by this review can be used by those conducting COI studies and those critiquing them, to increase the credibility and reporting of study results.

Entities:  

Mesh:

Year:  2015        PMID: 25576148     DOI: 10.1007/s40273-014-0250-y

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  90 in total

Review 1.  Economic evidence in affective disorders: a review.

Authors:  Mickael Löthgren
Journal:  Eur J Health Econ       Date:  2004-10

2.  Cost of affective disorders in Europe.

Authors:  P Andlin-Sobocki; H-U Wittchen
Journal:  Eur J Neurol       Date:  2005-06       Impact factor: 6.089

3.  Health care utilization and costs among patients treated for bipolar disorder in an insured population.

Authors:  G E Simon; J Unützer
Journal:  Psychiatr Serv       Date:  1999-10       Impact factor: 3.084

4.  The cost of relapse for patients with a manic/mixed episode of bipolar disorder in the EMBLEM study.

Authors:  Jihyung Hong; Catherine Reed; Diego Novick; Josep Maria Haro; Frank Windmeijer; Martin Knapp
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

5.  Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) program.

Authors:  Jinmei Li; Jeffrey S McCombs; Glen L Stimmel
Journal:  J Affect Disord       Date:  2002-09       Impact factor: 4.839

Review 6.  Clinical and economic effects of unrecognized or inadequately treated bipolar disorder.

Authors:  Paul E Keck; Ronald C Kessler; Ruth Ross
Journal:  J Psychiatr Pract       Date:  2008-05       Impact factor: 1.325

7.  The psychopathology of affectivity: conceptual and historical aspects.

Authors:  G E Berrios
Journal:  Psychol Med       Date:  1985-11       Impact factor: 7.723

8.  Treatment costs and health care utilization for patients with bipolar disorder in a large managed care population.

Authors:  Jeff J Guo; Paul E Keck; Hong Li; Raymond Jang; Christina M L Kelton
Journal:  Value Health       Date:  2007-12-17       Impact factor: 5.725

9.  In-patient care costs of patients with bipolar I disorder: a comparison between two European centers.

Authors:  A M Gonzalez-Pinto; R Dardennes; M de Zélicourt; P López; R G Oliveros; E Vieta; S Barbeito; E Echevarria; F Fagnani
Journal:  J Affect Disord       Date:  2009-05-31       Impact factor: 4.839

10.  Medication use, service utilization, and medical costs associated with new episodes of bipolar disorder: evidence from a retrospective claims database.

Authors:  Robert L Ohsfeldt; Maureen J Lage; Krithika Rajagopalan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007
View more
  12 in total

1.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

2.  Health status and mobility limitations are associated with residential and employment status in schizophrenia and bipolar disorder.

Authors:  M Strassnig; D Cornacchio; P D Harvey; R Kotov; L Fochtmann; E J Bromet
Journal:  J Psychiatr Res       Date:  2017-07-18       Impact factor: 4.791

3.  A genome-wide quantitative trait locus (QTL) linkage scan of NEO personality factors in Latino families segregating bipolar disorder.

Authors:  Byung Dae Lee; Suzanne Gonzalez; Erika Villa; Cynthia Camarillo; Marco Rodriguez; Yin Yao; Wei Guo; Deborah Flores; Alvaro Jerez; Henriette Raventos; Alfonso Ontiveros; Humberto Nicolini; Michael Escamilla
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-05-29       Impact factor: 3.358

4.  Critical factors for the return-to-work process among people with affective disorders: Voices from two vocational approaches.

Authors:  Susann Porter; Annika Lexén; Suzanne Johanson; Ulrika Bejerholm
Journal:  Work       Date:  2018

5.  Personality Structure and Attachment in Bipolar Disorder.

Authors:  Jolana Wagner-Skacel; Susanne Bengesser; Nina Dalkner; Sabrina Mörkl; Annamaria Painold; Carlo Hamm; René Pilz; Alexandra Rieger; Hans-Peter Kapfhammer; Michaela Hiebler-Ragger; Emanuel Jauk; Mary I Butler; Eva Z Reininghaus
Journal:  Front Psychiatry       Date:  2020-05-11       Impact factor: 4.157

6.  Obesity and metabolic comorbidity in bipolar disorder: do patients on lithium comprise a subgroup? A naturalistic study.

Authors:  Jake Prillo; Jocelyn Fotso Soh; Outi Linnaranta; Soham Rej; Haley Park; Serge Beaulieu
Journal:  BMC Psychiatry       Date:  2021-11-10       Impact factor: 3.630

7.  FGF21 Is Associated with Metabolic Effects and Treatment Response in Depressed Bipolar II Disorder Patients Treated with Valproate.

Authors:  Hui Hua Chang; Po See Chen; Yung Wen Cheng; Tzu-Yun Wang; Yen Kuang Yang; Ru-Band Lu
Journal:  Int J Neuropsychopharmacol       Date:  2018-04-01       Impact factor: 5.176

8.  Proteomic Profiling as a Diagnostic Biomarker for Discriminating Between Bipolar and Unipolar Depression.

Authors:  Sarah Kittel-Schneider; Tim Hahn; Frieder Haenisch; Rhiannon McNeill; Andreas Reif; Sabine Bahn
Journal:  Front Psychiatry       Date:  2020-04-17       Impact factor: 4.157

Review 9.  Real-World Patterns of Utilization and Costs Associated with Second-Generation Oral Antipsychotic Medication for the Treatment of Bipolar Disorder: A Literature Review.

Authors:  Michael J Doane; Kristine Ogden; Leona Bessonova; Amy K O'Sullivan; Mauricio Tohen
Journal:  Neuropsychiatr Dis Treat       Date:  2021-02-16       Impact factor: 2.570

10.  The costs of bipolar disorder in the United Kingdom.

Authors:  Judit Simon; Anees A Abdul Pari; Jane Wolstenholme; Michael Berger; Guy M Goodwin; John R Geddes
Journal:  Brain Behav       Date:  2021-09-15       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.